News | July 20, 2021
Balaxi Pharmaceuticals Q1 revenue increases by 12%
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
The country has constantly worked with the spirit of public-private partnership
Subscribe To Our Newsletter & Stay Updated
